Filing Details

Accession Number:
0000200406-12-000017
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-02-03 16:36:05
Reporting Period:
2012-02-01
Filing Date:
2012-02-03
Accepted Time:
2012-02-03 16:36:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
200406 Johnson & Johnson JNJ Pharmaceutical Preparations (2834) 221024240
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1189019 C William Weldon Johnson &Amp; Johnson
One Johnson &Amp; Johnson Plaza
New Brunswick NJ 08933
Chairman/Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-02-01 448,085 $52.20 783,708 No 4 M Direct
Common Stock Disposition 2012-02-01 448,085 $65.99 335,623 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2012-02-01 448,085 $0.00 448,085 $52.20
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2006-02-10 2013-02-08 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 32,582 Indirect By Wife
Common Stock 87,376 Indirect By GRAT
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $65.79 to $66.235. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  3. Awarded under Issuer's Stock Option Plan and exercisable in full starting three years from date of grant.